Why 20/20 Biolabs Inc (AIDX) Stock Is Rising
As of 2026-10-09, 20/20 Biolabs Inc (AIDX) has a next-year EPS growth estimate of 26.92%. Featured in our EPS revision report on 2026-10-09.
Why AIDX Stock Is Rising
- ·Current-Year Growth: Projected at 31.58%, supporting the forward estimate revision.
Current Snapshot
- Sector
- Healthcare
- Industry
- Medical Devices
- EPS growth next year
- 26.92%
- EPS growth this year
- 31.58%
- EPS next quarter (est)
- -$0.14
- Last price
- $0.38
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-09 | 26.92% | 31.58% | -$0.14 | $0.38 |
| 2026-10-08 | 26.92% | 31.58% | -$0.14 | $0.38 |
| 2026-10-07 | 26.92% | 31.58% | -$0.14 | $0.34 |
| 2026-10-06 | 26.92% | 31.58% | -$0.14 | $0.35 |
| 2026-10-05 | 26.92% | 31.58% | -$0.14 | $0.35 |
Reports Featuring AIDX
Screen Performance
Aggregate stats across all 2075 tickers our top-EPS-revision screen has flagged over the past 191 days.
- Median return since detection
- -0.8%
- % of tickers in the green
- 47%
- Median return on winners
- +22.5%
- Large revisions captured
- 1840
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did 20/20 Biolabs Inc (AIDX) stock go up recently?▾
20/20 Biolabs Inc (AIDX) stock has risen following an analyst upgrade of its next-year EPS growth estimate on 2026-10-05. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is 20/20 Biolabs Inc's next-year EPS growth estimate?▾
As of 2026-10-09, 20/20 Biolabs Inc (AIDX) has a next-year EPS growth estimate of 26.92%, based on analyst consensus.
What sector and industry does 20/20 Biolabs Inc belong to?▾
20/20 Biolabs Inc operates in the Healthcare sector, specifically the Medical Devices industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AIDX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. 20/20 Biolabs Inc (AIDX) appears here because it was detected by our daily top-EPS-revision-performer screen.